Non-profit generic drug company Civica Rx appoints former Amgen quality chief as new CEO
pharmafile | October 9, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Abbot, Amgen, Bayer, civica rx, generic drugs, hospitals
Civica Rx, a new not-for-profit generic drug company aimed at reducing the price of lifesaving medicines, has appointed former Amgen Chief Quality Officer, Senior Vice President Quality, Martin Van Trieste as their Chief Executive Officer (CEO).
Having joined Civica as a member of its board of advisors in September 2017 Van Trieste took on the position of CEO in September of this year. The experienced pharma professional brings more than 35 years of experience to the role having previously worked for pharma firms Abbot Laboratories, Amgen and Bayer.
However the Temple University graduate, who was ranked in second position on the Medicine Maker Power List of Industry Influencers, has agreed not to receive compensation for his leadership position in the non-profit initiative, due to the philanthropic nature of the organisation.
“We are creating a public asset with a mission to ensure that essential generic medications are accessible and affordable,” said VanTrieste. “The fact that a third of the country’s hospitals have either expressed interest or committed to participate with Civica Rx shows a great need for this initiative. This will improve the situation for patients by bringing much needed competition to the generic drug market”
As of now, the Utah-headquartered company has identified 14 hospital-administered generic medicines which will be the focus of the organisation’s initial efforts. The company aims to either directly manufacture these medicines themselves or sub -contract the manufacture of the generic drugs to reputable contract research organisations (CROs).
Although initially Civica Rx aims to stabilise the supply of essential generic medicines administered in hospitals, the long-term goal is to reduce the price of generic drugs overall. The company’s first products are expected to reach the market by 2019. The initiative is expected to save both hospitals and patients millions of dollars each year.
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …
FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …
